In cellulo and in vivo assays for compound testing against Trypanosoma cruzi.
Fiche publication
Date publication
janvier 2023
Journal
STAR protocols
Auteurs
Membres identifiés du Cancéropôle Est :
Dr ROMIER Christophe
Tous les auteurs :
Guerra-Slompo EP, Picchi-Constante GFA, Marek M, Romier C, Sippl W, Zanchin NIT
Lien Pubmed
Résumé
Here, we describe a combined in cellulo and in vivo approach to identify compounds with higher potential for efficient inhibition of Trypanosoma cruzi. Phase I of in cellulo assays is designed to exclude inactive or toxic compounds, while phase II is designed for accurate IC, CC, and selective index (SI) determination. Compounds showing high SI are tested using in vivo infection models in parallel with benznidazole to assess their efficacy relative to a reference drug used for Chagas disease treatment. For complete details on the use and execution of this protocol, please refer to Marek et al. (2021)..
Mots clés
Cell Biology, Cell-based Assays, High-throughput Screening, Microbiology, Model Organisms
Référence
STAR Protoc. 2023 01 24;4(1):102058